We used multivariate regression analyses to test whether markers of LCAT activity or altered lipid metabolism were associated with the prevalence of severe renal disease (CKD stage III–V/ESRD) in FLD patients (Table 7). The gene discussed is LCAT; the disease is chronic kidney disease.